A growing middle class in Brazil, Russia, India, China and other emerging markets offers an opportunity for life sciences companies to expand, but barriers have hindered some drugmakers' expansion efforts, writes Hussain Moorajis, global managing director at Accenture. Drugmakers need "an effective multifaceted strategy to get established, maintain competitiveness and drive profit," Moorajis writes, identifying six main challenges to expansion in emerging markets and offering a four-part approach to gaining a competitive edge.

Full Story:

Related Summaries